Form 4: Pulse Biosciences CTO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Pulse Biosciences' Chief Technology Officer, Darrin Uecker, executed a planned sale of 75,000 common shares in September 2025, following the exercise of stock options.
Summary
- Darrin Uecker, Chief Technology Officer and Director of Pulse Biosciences, Inc. (PLSE), reported multiple transactions involving the company's common stock.
- The transactions, totaling 75,000 shares, were conducted pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2025.
- On September 11, 2025, Uecker exercised options to acquire 25,000 shares at $4.00 per share and subsequently sold 25,000 shares at a weighted average price of $14.78.
- On September 12, 2025, Uecker exercised options to acquire another 25,000 shares at $4.00 per share and sold 25,000 shares at a weighted average price of $14.32.
- On September 15, 2025, Uecker exercised options for a final 25,000 shares at $4.00 per share and sold 25,000 shares at a weighted average price of $15.77.
- The stock options were granted in connection with Uecker's hire and became fully vested on September 8, 2019, four years after his start date.
- Following these transactions, Uecker's direct beneficial ownership of common stock is 122,872 shares, and he holds 106,534 derivative securities (stock options).
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be a negative signal, these transactions were pre-planned under a Rule 10b5-1 plan, mitigating concerns of opportunistic selling. The significant gain realized by the CTO also reflects positively on the company's stock performance since the options were granted.
Positives
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which indicates a planned liquidity event rather than a reaction to recent company performance.
- The sale prices of the common stock (ranging from $13.80 to $17.20 per share) are significantly higher than the exercise price of $4.00 per share, indicating a substantial gain for the insider and reflecting positive stock performance since the options were granted.
Negatives
- Insider selling, even if pre-planned, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.
Future Outlook
This Form 4 filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports past insider transactions.
Industry Context
This filing reports an individual insider transaction and does not provide broader industry context or trends. It reflects a personal financial decision by an executive, albeit a planned one, within the biotechnology sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Adoption | Darrin Uecker adopted a Rule 10b5-1 trading plan on June 12, 2025, which governed the reported transactions. This plan allows insiders to pre-arrange sales of company stock to avoid accusations of trading on material non-public information. | 06/12/2025 | The adoption of a 10b5-1 plan enhances transparency and reduces the perception of opportunistic insider trading, aligning with good corporate governance practices. |
Related Party Transactions
- The reported transactions involve the exercise of stock options and subsequent sale of common stock by Darrin Uecker, a Director and Chief Technology Officer of Pulse Biosciences, Inc., which constitutes a related party transaction.
Stakeholder Impact
- Shareholders: May view the insider selling as a liquidity event for the executive, especially given the pre-planned nature under Rule 10b5-1. The significant profit realized by the CTO could be seen as a positive indicator of past stock performance.
- Employees: No direct impact mentioned, but executive stock transactions can sometimes influence morale or perception of company value.
Key Dates
| Date | Description |
|---|---|
| 09/08/2015 | Date of Employment Agreement for Darrin Uecker |
| 09/08/2019 | Four-year anniversary of Darrin Uecker's start date, when stock options became fully vested |
| 06/12/2025 | Date Rule 10b5-1 trading plan was adopted by Darrin Uecker |
| 09/11/2025 | Transaction date: Exercise of 25,000 stock options and sale of 25,000 common shares |
| 09/12/2025 | Transaction date: Exercise of 25,000 stock options and sale of 25,000 common shares |
| 09/15/2025 | Transaction date: Exercise of 25,000 stock options and sale of 25,000 common shares; Signature date of reporting person |
| 09/20/2025 | Expiration date of the exercised stock options |
Recommendation
holdThe reported transactions are routine insider sales executed under a pre-arranged Rule 10b5-1 trading plan. While insider selling can sometimes be a bearish signal, the planned nature of these sales, coupled with the significant profit realized by the CTO from exercising options, suggests a personal liquidity event rather than a reflection of a negative outlook on the company's future. Without additional fundamental information, these transactions alone do not warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.
Keywords
Pulse Biosciences, PLSE, Darrin Uecker, Insider Transaction, Form 4, Stock Options, Rule 10b5-1, CTO, Share Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.